TVTX Travere Therapeutics, Inc.

NASDAQ
$51.10

Travere Therapeutics, Inc. (TVTX) is expected to report earnings on February 1, 2027, after the market close. The consensus earnings estimate is $0.33 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +9.9% since its last earnings release on November 2, 2026.

Travere Therapeutics Missed Consensus Estimates
Monday, November 2, 2026 · 4:01 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 1
Monday · 4:00 PM ET
Earnings Whisper
-
vs $0.33
Rev est $236.43M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $50.44

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Travere Therapeutics, Inc.

Travere Therapeutics Inc. is a biopharmaceutical company. It engages to identify, develop and deliver life-changing therapies. Travere Therapeutics Inc., formerly known as Retrophin Inc., is based in SAN DIEGO.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.